Precision Signals: James Gulley, MD, PhD

Endpoints, Resistance, and the Architecture of Evidence in Immuno-Oncology

5 hrs ago • 

Sean Khozin, MD, MPH

2

August 2025

The Misnomer of Surrogate Endpoints in Oncology

An Examination of a Fundamental Flaw in Regulatory Language and Scientific Precision

Aug 20 • 

Sean Khozin, MD, MPH

3

Precision Signals: Episode 2, Michelle Longmire, MD

A conversation on science, risk-taking, and the discipline of innovation

Aug 19 • 

Sean Khozin, MD, MPH

5

New Podcast Series: Precision Signals, Episode 1 with Olivier Elemento, PhD and Cora Sternberg, MD

AI in Oncology: Promise, Evidence, and the Threshold of Trust

Aug 12 • 

Sean Khozin, MD, MPH

2

The Three Waves of AI in Biomedicine: From Promise to Proof

How the next inflection point will make adoption irreversible

Aug 11 • 

Sean Khozin, MD, MPH

4

July 2025

From Breakthrough to Breakdown: The $900 Million FDA Rejection Letter

FDA's RP1 Rejection Signals Regulatory Transformation

Jul 22 • 

Sean Khozin, MD, MPH

9

3

The End of Disciplinary Sovereignty

Rethinking Expertise in the Era of Algorithmic Intelligence

Jul 11 • 

Sean Khozin, MD, MPH

4

2

June 2025

Beyond Gold Standards: Sins of Omission and Sins of Commission

The Perils of Precedent in Scientific Inquiry

Jun 12 • 

Sean Khozin, MD, MPH

3

1

May 2025

AI and the Reclamation of Scientific Abstraction

Redefining the Objects of Scientific Inquiry

May 18 • 

Sean Khozin, MD, MPH

3

2

Rebuilding American Generics Market

A Strategic Opportunity for Health Security and Market Resilience

May 4 • 

Sean Khozin, MD, MPH

2

1

April 2025

The Illusion Threshold: Reframing the Turing Test through Perceptual Intelligence

Toward a boundary condition for artificial general intelligence (AGI)

Apr 16 • 

Sean Khozin, MD, MPH

2

From Serendipity to Success: The Intricate Path of Biopharmaceutical Innovation

Reflections on "For Blood and Money"

Apr 1 • 

Sean Khozin, MD, MPH

2